세계의 정신건강 임상시험 시장 규모 조사 및 예측 : 단계별, 시험디자인별, 스폰서별, 질환별, 지역별 분석(2022-2029년)

Global Mental Health Clinical Trials Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. This are the clinics which deals with mental health problems. Throughout the course of the projection period, it is predicted that the global market for mental health clinical trials would expand significantly. The incidence of mental health illnesses, public awareness of mental health conditions, and increased funding from government agencies, businesses, hospitals, and universities are the main reasons driving the market's expansion. Moreover, rising number of mental illness and initiative by key market players are creating lucrative growth opportunity for the market over the forecast period.

Significant disruptions in thought, behavior, or emotional regulation characterize mental illnesses. According to a recent WHO report, 1 in every 8 people worldwide will have a mental condition in 2022. The two most prevalent mental illnesses, sadness, and anxiety, affected 970 million individuals worldwide in 2019.Worry, excessive fear, and accompanying behavioral abnormalities are hallmarks of anxiety disorders. According to 2019 WHO estimate, 58.0 million of the 301.0 million people with anxiety disorders are children and adolescents. There are numerous varieties of anxiety disorders, including generalized anxiety disorder, panic disorder, and social anxiety disorder. According to a scientific analysis by the WHO, the COVID-19 pandemic increased the prevalence of anxiety and depression globally by 25%. Stress brought on by the pandemic's social isolation is a significant factor. Depression and anxiety are caused by a variety of fears, including those of illness, pain, loneliness, money worries, and mourning following a loss. However, the high cost of Mental Health Clinical Trials stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Mental Health Clinical Trials Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. Due to factors similar to increased R&D spending, supportive government policies, and growth in the use of innovative technologies in clinical trials, North America is predicted to have the largest market share throughout the projection period. Clinicaltrials.org reports that from 2019 to 2021, 52% of all registered clinical trials for depression would be conducted in the region. Also, from 2019 to 2021, the region's trial percentage will rise from 45.9% to 50.9%. Along with this, Asia-Pacific is growing with the fastest CAGR over the forecast period owing to the rising number of clinical trials.

Major market players included in this report are:

• ICON Plc.
• Eli Lilly and Company
• Caidya
• Syneous Health
• Novo Nordisk AS
• Pharmaceutical Product Development, LLC
• Parexel International Corporation
• Corcept Therapeutics Incorporated (Corcept)
• Labcorp Drug Development
• IQVIA, Inc.

Recent Developments in the Market:

• In September 2022, the launch of Epic's Life Sciences division broadens its efforts to reunite the fragmented elements of the healthcare system. The goals of the program is to include facilitating the recruitment of research participants, accelerating the development of novel treatments for providers, and increasing access to clinical trials for underrepresented populations, pharmaceutical firms, and medical device manufacturers.

Global Mental Health Clinical Trials Market Report Scope:

• Historical Data: 2019-2020-2021

• Base Year for Estimation: 2021

• Forecast period: 2022-2029

• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

• Segments Covered: Study Design, Sponsor, Disorder, Region

• Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World

• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Study Design offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Phase:

• Phase I
• Phase II
• Phase III
• Phase IV

By Study Design:

• Interventional
• Observational
• Expanded Access

By Sponsor:

• Pharmaceutical & Biopharmaceutical Companies
• Government Agencies
• Others

By Disorder:

• Anxiety Disorders
• Depression
• Bipolar affective disorder
• Dissociation and dissociative disorders
• Schizophrenia
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Rest of the World

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
  • 1.2.1. Mental Health Clinical Trials Market, by Region, 2019-2029 (USD Billion)
  • 1.2.2. Mental Health Clinical Trials Market, by Study Design, 2019-2029 (USD Billion)
  • 1.2.3. Mental Health Clinical Trials Market, by Sponsor, 2019-2029 (USD Billion)
  • 1.2.4. Mental Health Clinical Trials Market, by Disorder, 2019-2029 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Mental Health Clinical Trials Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Scope of the Study
  • 2.2.2. Industry Evolution
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Mental Health Clinical Trials Market Dynamics

• 3.1. Mental Health Clinical Trials Market Impact Analysis (2019-2029)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Increasing government funding
    • 3.1.1.2. Growing number of clinical trials
  • 3.1.2. Market Challenges
    • 3.1.2.1. High Cost of Mental Health Clinical Trials
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Rising number of mental illnesses
    • 3.1.3.2. Rising initiatives by the key market players

Chapter 4. Global Mental Health Clinical Trials Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
• 4.4. Investment Adoption Model
• 4.5. Analyst Recommendation & Conclusion
• 4.6. Top investment opportunity
• 4.7. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

• 5.1. Assessment of the overall impact of COVID-19 on the industry
• 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Mental Health Clinical Trials Market, by Phase

• 6.1. Market Snapshot
• 6.2. Global Mental Health Clinical Trials Market by Phase, Performance - Potential Analysis
• 6.3. Global Mental Health Clinical Trials Market Estimates & Forecasts by Phase 2019-2029 (USD Billion)
• 6.4. Mental Health Clinical Trials Market, Sub Segment Analysis
  • 6.4.1. Phase I
  • 6.4.2. Phase II
  • 6.4.3. Phase III
  • 6.4.4. Phase IV

Chapter 7. Global Mental Health Clinical Trials Market, by Study Design

• 7.1. Market Snapshot
• 7.2. Global Mental Health Clinical Trials Market by Study Design, Performance - Potential Analysis
• 7.3. Global Mental Health Clinical Trials Market Estimates & Forecasts by Study Design 2019-2029 (USD Billion)
• 7.4. Mental Health Clinical Trials Market, Sub Segment Analysis
  • 7.4.1. Interventional
  • 7.4.2. Observational
  • 7.4.3. Expanded Access

Chapter 8. Global Mental Health Clinical Trials Market, by Sponsor

• 8.1. Market Snapshot
• 8.2. Global Mental Health Clinical Trials Market by Sponsor, Performance - Potential Analysis
• 8.3. Global Mental Health Clinical Trials Market Estimates & Forecasts by Sponsor 2019-2029 (USD Billion)
• 8.4. Mental Health Clinical Trials Market, Sub Segment Analysis
  • 8.4.1. Pharmaceutical & Biopharmaceutical Companies
  • 8.4.2. Government Agencies
  • 8.4.3. Others

Chapter 9. Global Mental Health Clinical Trials Market, by Disorder

• 9.1. Market Snapshot
• 9.2. Global Mental Health Clinical Trials Market by Disorder, Performance - Potential Analysis
• 9.3. Global Mental Health Clinical Trials Market Estimates & Forecasts by Disorder 2019-2029 (USD Billion)
• 9.4. Mental Health Clinical Trials Market, Sub Segment Analysis
  • 9.4.1. Anxiety Disorders
  • 9.4.2. Depression
  • 9.4.3. Bipolar affective disorder
  • 9.4.4. Dissociation and dissociative disorders
  • 9.4.5. Schizophrenia
  • 9.4.6. Others

Chapter 10. Global Mental Health Clinical Trials Market, Regional Analysis

• 10.1. Mental Health Clinical Trials Market, Regional Market Snapshot
• 10.2. North America Mental Health Clinical Trials Market
  • 10.2.1. U.S. Mental Health Clinical Trials Market
    • 10.2.1.1. Phase breakdown estimates & forecasts, 2019-2029
    • 10.2.1.2. Study Design breakdown estimates & forecasts, 2019-2029
    • 10.2.1.3. Sponsor breakdown estimates & forecasts, 2019-2029
    • 10.2.1.4. Disorder breakdown estimates & forecasts, 2019-2029
  • 10.2.2. Canada Mental Health Clinical Trials Market
• 10.3. Europe Mental Health Clinical Trials Market Snapshot
  • 10.3.1. U.K. Mental Health Clinical Trials Market
  • 10.3.2. Germany Mental Health Clinical Trials Market
  • 10.3.3. France Mental Health Clinical Trials Market
  • 10.3.4. Spain Mental Health Clinical Trials Market
  • 10.3.5. Italy Mental Health Clinical Trials Market
  • 10.3.6. Rest of Europe Mental Health Clinical Trials Market
• 10.4. Asia-Pacific Mental Health Clinical Trials Market Snapshot
  • 10.4.1. China Mental Health Clinical Trials Market
  • 10.4.2. India Mental Health Clinical Trials Market
  • 10.4.3. Japan Mental Health Clinical Trials Market
  • 10.4.4. Australia Mental Health Clinical Trials Market
  • 10.4.5. South Korea Mental Health Clinical Trials Market
  • 10.4.6. Rest of Asia Pacific Mental Health Clinical Trials Market
• 10.5. Latin America Mental Health Clinical Trials Market Snapshot
  • 10.5.1. Brazil Mental Health Clinical Trials Market
  • 10.5.2. Mexico Mental Health Clinical Trials Market
• 10.6. Rest of The World Mental Health Clinical Trials Market

Chapter 11. Competitive Intelligence

• 11.1. Top Market Strategies
• 11.2. Company Profiles
  • 11.2.1. ICON Plc.
    • 11.2.1.1. Key Information
    • 11.2.1.2. Overview
    • 11.2.1.3. Financial (Subject to Data Availability)
    • 11.2.1.4. Product Summary
    • 11.2.1.5. Recent Developments
  • 11.2.2. Eli Lilly and Company
  • 11.2.3. Caidya
  • 11.2.4. Syneous Health
  • 11.2.5. Novo Nordisk AS
  • 11.2.6. Pharmaceutical Product Development, LLC
  • 11.2.7. Parexel International Corporation
  • 11.2.8. Corcept Therapeutics Incorporated (Corcept)
  • 11.2.9. Labcorp Drug Development
  • 11.2.10. IQVIA, Inc.

Chapter 12. Research Process

• 12.1. Research Process
  • 12.1.1. Data Mining
  • 12.1.2. Analysis
  • 12.1.3. Market Estimation
  • 12.1.4. Validation
  • 12.1.5. Publishing
• 12.2. Research Attributes
• 12.3. Research Assumption